We are live on ! Find out more
HRMY icon

Harmony Biosciences
HRMY

279 hedge funds and large institutions have $1.62B invested in Harmony Biosciences in 2025 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 127 increasing their positions, 70 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

366% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $2.26M

81% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 70

26% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 31

3% more funds holding

Funds holding: 272 → 279 (+7)

1.59% more ownership

Funds ownership: 87.66% → 89.25% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less capital invested

Capital invested by funds: $1.67B → $1.62B (-$47.1M)

Holders
279
Holders Change
+7
Holders Change %
+2.57%
% of All Funds
3.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
39
Increased
127
Reduced
70
Closed
31
Calls
$10.5M
Puts
$2.26M
Net Calls
+$8.27M
Net Calls Change
+$4.89M

Top Buyers

Rank Fund Capital Flow
1
Boston Partners
Boston Partners
Massachusetts
+$19.5M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$16.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13.2M
4
Goldman Sachs
Goldman Sachs
New York
+$12.1M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$11.5M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$27.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$21M
3
NVCHI
New Vernon Capital Holdings II
New Jersey
-$15.2M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
-$10.3M
5
JP Morgan Chase
JP Morgan Chase
New York
-$9.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
301
Polymer Capital Management
New York
– -$219K -6,602 Closed
FRM
302
Fox Run Management
Connecticut
– -$201K -6,071 Closed
QCG
303
Quadrant Capital Group
Ohio
– -$89.7K -2,703 Closed
GWM
304
Geneos Wealth Management
Colorado
– -$13.4K -405 Closed
FHA
305
First Horizon Advisors
Tennessee
– -$1.13K -34 Closed
TWD
306
True Wealth Design
Ohio
– -$797 -24 Closed
BIA
307
Bell Investment Advisors
California
– -$764 -23 Closed
SC
308
Stephens Consulting
Michigan
– -$332 -10 Closed
GFPC
309
Global Financial Private Client
Florida
– -$199 -6 Closed
HWM
310
Hemington Wealth Management
Virginia
– +$450 +14 +100%
9 10 11 12
13

HRMY Hedge Fund Activity: Q2 2025 in Review

279 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2025, worth a combined $1.62B — down 2.8% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new HRMY positions and 31 closed out — a net gain of 8 holders — while 127 added to existing stakes and 70 trimmed.

The largest buyer was Boston Partners, opening a new position worth an estimated $19.5M. The largest seller was Citadel Advisors, exiting entirely with an estimated $27.7M sold.

  • 279 institutional investors held Harmony Biosciences (HRMY) as of Q2 2025, up from 272 in Q1 2025.
  • Funds reported $1.62B of Harmony Biosciences stock for Q2 2025, down 2.8% quarter-over-quarter.
  • 39 funds opened new Harmony Biosciences positions in Q2 2025 and 31 closed out, a net change of +8 holders.
  • The largest Harmony Biosciences buyer in Q2 2025 was Boston Partners, an estimated $19.5M added.
  • The largest Harmony Biosciences seller in Q2 2025 was Citadel Advisors, an estimated $27.7M sold.

Based on aggregated 13F filings for Q2 2025.